Updated:
MedEquity Capital
Ingersoll and Ward launched MedEquity Capital in Waltham, Massachusetts after careers spanning Bain & Company and PaineWebber healthcare investment...
MedEquity Capital
Ingersoll and Ward launched MedEquity Capital in Waltham, Massachusetts after careers spanning Bain & Company and PaineWebber healthcare investment banking, respectively. Each partner brought over 25 years of operating and investing experience in healthcare, and the firm's model reflects that: partners don't just sit on boards, they step into CEO, CFO, and Operating Chairman roles at their portfolio companies. The firm commits control or significant minority equity across provider-based services, specialty pharmacy, outsourcing, and technology-enabled healthcare services. Platform investments typically carry $5 million or more in revenue, while tuck-in acquisitions have no minimum size. Confirmed portfolio companies include PharmaLogic, Belmar Pharma Solutions, MAX Surgical Specialty Management, AppleCare Immediate Care, and Qler Solutions. MedEquity concentrates on privately owned businesses in the United States seeking direct transactions outside formal auction processes — a sourcing advantage it attributes to two decades of relationships with industry executives and financial institutions. MedEquity operates with a lean investment team of four disclosed professionals led by the two founding partners. Brandon Ingersoll currently serves as Operating Chairman of both PharmaLogic and Belmar Pharma Solutions, while Jeff Ward leads MAX Surgical Specialty Management as CEO. The firm has demonstrated an appetite for roll-ups: under Ingersoll's chairmanship, PharmaLogic expanded from four to over 45 pharmacies. The team's activity in recent years includes Belmar Pharma Solutions growing from two locations in one state to five locations across four states. The firm's structural differentiator is its operator-heavy governance. Unlike many private equity firms that rely on outside executives, MedEquity embeds its own partners directly into portfolio company management — Ingersoll and Ward have each held multiple C-suite roles across investments simultaneously. This hands-on posture is designed to execute consolidation strategies in fragmented healthcare sub-sectors without the friction of recruiting external operating partners.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Waltham
Corporate office
135 Beaver Street, Suite 400 Waltham, MA 02452, United States
Principals
W. Brandon Ingersoll
Founding Partner
Jeffrey T. Ward
Founding Partner
Tom Beausejour
Principal
Leland Garrahan
Vice President
Sector focus
Frequently asked questions
Who runs investment decisions at MedEquity Capital?
Founding partners W. Brandon Ingersoll and Jeffrey T. Ward lead investment decisions, supported by Principal Tom Beausejour and Vice President Leland Garrahan. Ingersoll and Ward each have over 25 years of healthcare experience and have held CEO or Chairman roles at multiple portfolio companies. Beausejour joined in 2016 from Vertex Pharmaceuticals, while Garrahan joined after consulting roles at L.E.K. and Accenture (per the firm).
Does MedEquity Capital participate in fund commitments or only direct deals?
The firm structures its investments through preferred equity or blended securities, taking control or significant minority positions in portfolio companies. All disclosed investments are direct platform acquisitions or tuck-in buyouts, typically of founder- or family-owned healthcare businesses. MedEquity does not publicly report operating a fund-of-funds or participating as a limited partner in third-party vehicles.
How does MedEquity Capital source proprietary deal flow?
MedEquity states that many of its prospects are privately owned businesses seeking a transaction on a direct basis or outside a formal auction process. The firm credits long-term relationships with industry executives and financial institutions for access to these opportunities. The two founders have operated in healthcare for more than two decades, giving them direct reach into the lower middle market where personal networks dominate deal origination.
What investment stages does MedEquity Capital typically target?
The firm targets buyout and growth capital investments in established, profitable companies with strong cash flow. For platform investments, MedEquity seeks companies with at least $5 million in revenue and $1 million to $10 million in EBITDA. Tuck-in acquisitions have no revenue or EBITDA minimum. The firm also selectively considers recapitalizations that provide full or partial liquidity to owners.
Which sectors does MedEquity Capital explicitly avoid?
MedEquity states it will rarely invest in a specific technology, product, or compound, preferring healthcare service or distribution businesses that can capitalize on broad technology trends without taking obsolescence risk. The firm does not back early-stage life sciences companies or businesses with significant regulatory approval dependencies, focusing instead on cash-flowing service providers and specialty pharmacies.
What is MedEquity Capital's posture on co-investments alongside external GPs?
The firm has not publicly disclosed a co-investment program for external limited partners. MedEquity's capital deployment model appears to rely on direct platform and add-on acquisitions sourced through its own network. There is no public record of the firm syndicating equity to institutional co-investors or operating a club-deal structure.
Where does MedEquity Capital's underlying capital come from?
MedEquity does not publicly disclose its limited partner base. The firm was founded by Ingersoll and Ward, who self-describe as having generated returns for company founders and investors that exceed peer benchmarks (per the firm). Without a disclosed wealth-origin event or institutional LP roster, the exact composition of its capital base remains private.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: